MASLD管理中无创检测替代肝活检添新证据:突破还是挑战？

摘要/Abstract

摘要： 代谢相关脂肪性肝病(MASLD)与肥胖、代谢综合征、2型糖尿病密切相关。随着全球肥胖和糖尿病的流行,MASLD疾病负担日益加重。肝活检一直被视为诊断MASLD和评估肝病严重程度的“金标准”,但侵入性和局限性限制其在临床应用。血清生物标志物、影像学技术等无创检测方法在评估MASLD纤维化方面显示巨大潜力。其中,结合了振动控制瞬时弹性成像(VCTE)与常规生物标志物的Agile评分系统,能够识别MASLD相关进展性纤维化和肝硬化,并预测MASLD患者肝脏相关事件,为临床监测肝病进展提供新的标志物。尽管这些无创方法同样存在一些局限性,但它们为MASLD的诊断和管理提供了新工具,未来的研究和技术创新有望进一步完善这些方法,从而为患者提供更准确、更安全的诊疗方案。

曾静, 范建高. MASLD管理中无创检测替代肝活检添新证据:突破还是挑战？[J]. 肝脏, 2024, 29(5): 491-493.

/ 推荐

参考文献

[1] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023, 79(6): 1542-1556.
[2] Younossi ZM, Golabi P, Paik JM. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347.
[3] Yip TCF, Fan JG, Wong VWS. China’s Fatty Liver Crisis: A Looming Public Health Emergency[J]. Gastroenterology, 2023, 165(4): 825-827.
[4] Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD[J]. J Hepatol, 2024, 80(2): e62-e64.
[5] Tsochatzis EA. Natural history of NAFLD: knowns and unknowns[J]. Nat Rev Gastroenterol Hepatol, 2021, 19(3): 151-152.
[6] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2019, 71(4): 793-801.
[7] Taylor RS, Taylor RJ, Bayliss S, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis[J]. Gastroenterology, 2020, 158(6): 1611-1625.e1612.
[8] Li J, Delamarre A, Wong VWS, et al. Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease[J]. United Eur Gastroenterol J, 2023, 12(2): 219-225.
[9] Younes R, Caviglia GP, Govaere O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2021, 75(4): 786-794.
[10] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835.
[11] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update[J]. J Hepatol, 2021, 75(3): 659-689.
[12] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)[J]. Endocr Pract, 2022, 28(5): 528-562.
[13] Boursier J, Hagström H, Ekstedt M, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events[J]. J Hepatol, 2022, 76(5): 1013-1020.
[14] Cassinotto C, Boursier J, de Lédinghen V, et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy[J]. Hepatology, 2016, 63(6): 1817-1827.
[15] Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis[J]. J Hepatol, 2021, 75(4): 770-785.
[16] Canivet CM, Costentin C, Irvine KM, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD[J]. Hepatology, 2023, 77(3): 920-930.
[17] Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4): 362-373.
[18] Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores[J]. J Hepatol, 2023, 78(2): 247-259.
[19] Lin H, Lee HW, Yip TC-F, et al. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease[J]. JAMA, 2024,331(15):1287-1297.
[20] Younossi ZM. Predicting Liver-Related Outcomes in Steatotic Liver Disease[J]. JAMA, 2024, 331(15):1274-1275.